<DOC>
	<DOCNO>NCT01149473</DOCNO>
	<brief_summary>The objective study compare relative bioavailability Losartan potassium/Hydrochlorothiazide 100/25 mg tablet ( manufacture Teva Pharmaceutical Industries , Ltd. distribute Teva Pharmaceuticals USA ) HyzaarÂ® 100/25 mg tablet ( Merck ) healthy , adult , non-smoking subject non-fasting condition .</brief_summary>
	<brief_title>Losartan Potassium/Hydrochlorothiazide 100/25 mg Tablets Healthy Subjects Under Non-Fasting Conditions</brief_title>
	<detailed_description>Criteria Evaluation : FDA Bioequivalence Criteria Statistical Methods : FDA Bioequivalence Statistical Methods</detailed_description>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<criteria>Healthy , nonsmoking , male female subject least 18 year age . BMI ( body mass index ) 30 less . Females study must physically unable become pregnant ( postmenopausal least 6 month surgically sterile ) . Successful completion physical examination within 28 day initiation study . Negative serum pregnancy test ( female ) . Subjects significant recent history chronic alcohol consumption ( past 2 year ) , drug addiction , serious gastrointestinal , renal , hepatic , cardiovascular disease , tuberculosis , epilepsy , asthma ( past 5 year ) , diabetes , psychosis , glaucoma eligible study . Subjects whose clinical laboratory test value outside reference range deem clinically significant Principle Investigator . Subjects history allergic response class drug test exclude study . Subjects use tobacco form eligible participate study . 3 month abstinence require . Subjects find urine concentration test drug abuse allow participate . Subjects donate blood and/or plasma least 30 day prior first dose study . Subjects take investigational drug within 30 day prior first dose study allow participate . Female subject pregnant able ( woman child bear potential ) become pregnant study allow participate . All female subject screen pregnancy checkin study period . Subjects positive inconclusive result withdrawn study . Subjects tolerate venipuncture allow participate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Healthy Subjects</keyword>
</DOC>